EN DE

Novoray Corporation (688300) Fair Value & Analysis

Basic Materials · CN · Market cap 35.3B CNY (≈ $5.3B) · ISIN CNE100003PN0

NC Novoray Corporation 688300 · SHG
Price¥186.24
Fair Value¥19.41
Upside-89.6%
Quality70/100

Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.

Watch Novoray Corporation for free, get notified when fair value or trend changes. Watch for free

Strengths

Highly profitable · 25.7% net margin
Low debt · generates free cash flow
Wide moat 80/100

Risks

!Trades 860% ABOVE our fair value of ¥19.41
!Mixed Growth (revenue 5y +22.5 %/yr)
!Mixed vs. peers (7/14)
!Evidence only medium, so the estimate is less certain
Mixed Growth (revenue 5y +22.5 %/yr)
Highly profitable · 25.7% net margin
Low debt · generates free cash flow
0.34% dividend yield
Mixed vs. peers (7/14)
Wide moat 80/100
Evidence: Medium Range ¥10.67 – ¥27.43 Share as image

Fair value as of: Aug 17, 2026

From 26 valuation models · updated 11 days ago

Share price +56.8% over the past month.

A solid business, but trading 860% above our fair value.

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Track Novoray Corporation and get told automatically when its fair value or trend turns, plus fair value for all 35,000+ stocks. 14 days of Pro free, no card. Track it free

What matters now

  • A high-quality business (quality 70/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
  • The price sits above even our optimistic bull case (¥27.43). The favourable scenario is already priced in.
  • A fairly wide model range (¥10.67 to ¥27.43) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

¥272.54 ¥16.86 Fair Value ¥19.41 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 17, 2026.

How to read this chart

60‑month range ¥16.86 – ¥272.54 · fair‑value band ¥10.67 – ¥27.43 · the ¥186.24 price screens above the ¥19.41 fair value. Dashed = 300-day average. As of Aug 17, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Novoray Corporation (688300) currently trades at ¥186.24, while our model-based Fair Value estimate is ¥19.41, implying the stock looks roughly 89.6% overvalued today. The Quality Score stands at 70/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Novoray Corporation generated revenue of 1.2B CNY at a net margin of 25.7%. Revenue grew 23.2% year over year. It earns a return on equity of 17.7%. Net debt stands at 9.6M CNY. Fundamentals as of Aug 17, 2026

Our scenario range runs from ¥10.67 (bear case) to ¥27.43 (bull case); at ¥186.24, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 14% below its 52-week high and 346% above its 52-week low, currently above its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -59% fair-value upside, at -90%, 688300 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Note: the current price implies far more future growth than the conservative anchors of our models allow (base growth is deliberately capped, we do not regard such extreme rates as sustainable). Our models are not designed for expectations this high; that is why the individual models scatter extremely (¥4.53 to ¥57.47). Read the values as a conservative anchor, not as a price target.
Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF ¥10.31 ¥19.68 ¥37.59 80
Residual Income ¥8.00 ¥10.55 ¥37.43 76
Rev-Margin DCF ¥7.07 ¥12.74 ¥21.21 74
All 26 models by family
DCF Models
FCF DCF ¥10.79 ¥17.75 ¥37.75 38
Owner Earnings ¥17.10 ¥38.27 ¥82.71 31
5Y Revenue Exit ¥7.07 ¥11.98 ¥21.45 39
5Y EBITDA Exit ¥12.09 ¥22.85 ¥42.56 41
5Y P/E Exit ¥14.31 ¥30.25 ¥50.91 38
10Y Revenue Exit ¥7.95 ¥14.50 ¥21.82 36
10Y EBITDA Exit ¥11.69 ¥24.05 ¥46.78 37
10Y P/E Exit ¥13.25 ¥28.27 ¥54.44 35
Earnings-Based
Graham-Dodd ¥8.24 ¥57.47 ¥80.65 54
Lynch FV ¥17.19 ¥24.55 ¥31.92 50
PEG = 1.0 ¥17.19 ¥24.55 ¥31.92 46
EPV ¥12.10 ¥14.03 ¥15.72 59
Dividend Discount
Gordon GGM ¥3.54 ¥7.35 ¥11.66 70
DDM Multi-Stage ¥3.54 ¥6.20 ¥7.71 61
Multiples
P/E Multiple ¥15.45 ¥20.60 ¥25.75 63
P/S Multiple ¥5.20 ¥6.93 ¥8.66 58
P/B Multiple ¥15.22 ¥20.29 ¥25.37 55
EV/EBIT ¥15.10 ¥19.96 ¥24.82 53
EV/EBITDA ¥12.82 ¥16.93 ¥21.03 54
EV/Revenue ¥5.36 ¥7.44 ¥9.52 43
Asset-Based
NCAV (Graham) ¥3.38 ¥4.53 ¥6.76 50
Growth DCF
Growth DCF ¥10.31 ¥19.68 ¥37.59 80
Rev-Margin DCF ¥7.07 ¥12.74 ¥21.21 74
Economic Profit
Residual Income ¥8.00 ¥10.55 ¥37.43 76
ROIC Compounder ¥15.02 ¥22.08 ¥30.06 72
Growth Earnings
Growth-Adj P/E ¥21.51 ¥30.73 ¥39.95 68

Widest divergence: Growth Earnings (¥30.73) versus Asset-Based (¥4.53). Highest evidence: Growth DCF (80).

Notify me when 688300 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 149.0
P/S ratio 39.1 P/E × margin
EPS (TTM) ¥1.25 price ÷ EPS = P/E 149.0
Dividend yield 0.3% payout 50.7%
Net margin 26.2% FY2025
Return on equity 17.7% TTM
More key figures
Profitability
Return on assets (EBIT) 13.6% avg 5y
Operating margin 28.9% TTM
Growth
Revenue (TTM) 1.2B CNY TTM
Revenue growth (YoY) +23.2% 3y avg +19.0%
EPS growth (YoY) +15.4%
Balance sheet & cash flow
Free cash flow 157M CNY FY2025
Net debt 9.6M CNY FY2025 · ≈ 0.1 yrs of FCF

Figures from reported company fundamentals · as of Aug 17, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 70/100

Of which business quality 67 · Market factors (momentum, volatility) 66

Profitability 73
Margins and returns on capital today
Quality Growth 63
Are margins and returns improving?
Cashflow 53
Earnings quality: real cash, not paper profit
Fin. Strength 79
Balance sheet, leverage, solvency risk
Investment 48
Disciplined investing over empire-building
Low Volatility 22
Calm price path (market factor)
Momentum 88
Price trend over the last 3–12 months (market factor)
52W Momentum 78
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Novoray Corporation provides industrial powder materials in China and internationally. The company offers crystalline silica powder, fused silica powder, soft composite silica powder, round corner crystalline silica powder, spherical silica powder, spherical aluminum oxide powder, sub-micron spherical silica powder, and acicular powder.

Full company description

Novoray Corporation provides industrial powder materials in China and internationally. The company offers crystalline silica powder, fused silica powder, soft composite silica powder, round corner crystalline silica powder, spherical silica powder, spherical aluminum oxide powder, sub-micron spherical silica powder, and acicular powder. It serves electronic materials, electrical insulating materials, ceramics, precision casting, paints and coatings, silicon rubber, functional rubber, plastics, and building materials manufacturing industries. Novoray Corporation was founded in 2002 and is based in Lianyungang, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Novoray Corporation reported revenue of ¥1.1B in FY2025 versus ¥625M in FY2021, a compound +15.6%/yr. Reported net income was ¥293M in FY2025, compounding +14.1%/yr from FY2021.

Growth Quality 91/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
1.1B CNY
Latest YoY
+16.2%
Avg. revenue growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+19.0%
Avg. revenue growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+22.5%
Avg. revenue growth/yr (13Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+19.6%
Value creation/yr (5Y) Earnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
+21.7% (21.4 + 0.3)
Revenue +15.6%/yr
FY21 ¥625M
FY22 ¥662M
FY23 ¥712M
FY24 ¥960M
FY25 ¥1.1B
Net income +14.1%/yr
FY21 ¥173M
FY22 ¥188M
FY23 ¥174M
FY24 ¥251M
FY25 ¥293M
Character of growth · EPS growth decomposed (2014-2025) +10.3 % p.a.
Revenue per share +5.6 pp

of which total revenue +24.0 pp · buybacks/dilution −18.5 pp

EBIT margin +7.1 pp
Tax rate +0.2 pp
Residual (interest, one-offs) −2.6 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

688300 screens 90% overvalued. Compare with Linde plc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Novoray Corporation Fair Value". https://www.fairvalue-calculator.com/stock/688300

Peer Group

Specialty Chemicals · 713 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 70 · Top 25%
Fair Value upside −90% · Bottom 25%
Return on equity (TTM) 18% · Top 25%
Return on assets 8% · Top 25%
Net margin (TTM) 26% · Top 25%
Operating margin (TTM) 29% · Top 25%
Revenue growth 23% · Top 25%
Dividend yield (TTM) 0.3% · Bottom 25%
Debt / equity 0.01× · Lower than 75% of peers

Valuation Multiples vs Specialty Chemicals median · lower = cheaper

P/E (TTM) 149.0× · Pricier than 75% of peers
P/B 21.59× · Pricier than 75% of peers
P/S (TTM) 30.11× · Pricier than 75% of peers
P/FCF 33.4× · Pricier than 75% of peers
EV/EBITDA 91.1× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 0
FUTURE100 · sector 19
PAST71 · sector 23
HEALTH100 · sector 95
DIVIDEND5 · sector 29

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Aug 17, 2026).

Stock Price Fair Value vs Fair Value
Linde plc LIN $490.33 $222.03 -55%
The Sherwin-Williams Company SHW $348.66 $143.38 -59%
Ecolab Inc ECL $290.60 $96.18 -67%
Air Products and Chemicals, Inc APD $306.66 $122.14 -60%
Givaudan SA GIVN CHF 3,274 CHF 1,498 -54%
Wanhua Chemical Group 600309 ¥75.06 ¥68.03 -9%
500820 500820 ₹2,757 ₹557.43 -80%
Novozymes A/S NSISB kr 456.40 kr 169.99 -63%
Asian Paints Limited ASIANPAINT ₹2,630 ₹696.23 -74%
PPG Industries, Inc PPG $114.42 $71.31 -38%

Compare Novoray Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Fama-French 3-Factor Model Calculator Run the Fama-French 3-factor model in seconds: expected return from the market, size and value factors - free, with formula, betas and an example. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Novoray Corporation (688300) overvalued or undervalued?
As of Aug 17, 2026, our model estimates a fair value of ¥19.41 versus a price of ¥186.24, about −90% (overvalued).
What is the fair value of 688300?
Our model-based fair value for Novoray Corporation is ¥19.41 (as of Aug 17, 2026), built from audited fundamentals. The current price: ¥186.24.
What is the quality score of 688300?
Novoray Corporation has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Novoray Corporation (688300)?
Novoray Corporation reported trailing-twelve-month revenue of about 1.2B CNY (latest available figure, as of Aug 17, 2026).
What is the net profit margin of 688300?
The net profit margin of Novoray Corporation is about 25.7%, meaning it keeps roughly 25.7% of revenue as net income. Based on the latest reported figures.
Does Novoray Corporation pay a dividend?
Novoray Corporation currently shows a dividend yield of about 0.27% relative to its recent price (as of Aug 17, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

Free · no account needed

Watch Novoray Corporation in the live analysis

One click puts Novoray Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.